Olema Pharmaceuticals announced new preclinical data for palazestrant, a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader, alone and in combination with OP-3136, a novel small molecule that potently and selectively inhibits acetyltransferase 6 (KAT6) inhibitor. The data will be presented in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22 in San Diego, California.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Oncology initiated with a Peer Perform at Wolfe Research
- Olema Oncology assumed with a Buy at Jefferies
- Olema Oncology price target raised to $58 from $55 at JPMorgan
- Olema Oncology price target lowered to $27 from $38 at Goldman Sachs
- Olema Oncology price target lowered to $38 from $40 at Guggenheim